Madrigal Pharmaceuticals (MDGL) vs Rhythm Pharmaceuticals (RYTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rhythm Pharmaceuticals (RYTM) has outperformed Madrigal Pharmaceuticals (MDGL) over the past year, gaining 10.4% versus a loss of 30.8%. Over five years, RYTM leads with a +1116.0% price change compared with +362.0% for MDGL. Madrigal Pharmaceuticals is the larger company by market cap ($8.81 billion vs $7.79 billion), about 1.1 times the size.
Madrigal Pharmaceuticals converts more of its revenue into profit, with a net margin of -30.1% versus -103.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDGL | RYTM |
|---|---|---|
| Share price | $379.10 | $112.36 |
| Market cap | $8.81B | $7.79B |
| 1-day change | -4.45% | -3.80% |
| YTD return | -34.90% | +4.97% |
| 1-year return | -30.82% | +10.44% |
| 5-year return | +361.98% | +1116.02% |
| Forward P/E | 36.52 | — |
| EPS (TTM) | $-5.85 | $-2.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $958.40M | $189.76M |
| Revenue growth (YoY) | +432.05% | +45.83% |
| Net income (latest FY) | $-288.28M | $-196.54M |
| Gross margin | — | 89.73% |
| Operating margin | -31.31% | -101.19% |
| Net margin | -30.08% | -103.57% |
| 52-week high | $615.00 | $122.20 |
| 52-week low | $353.54 | $74.50 |
| Distance from 52-week high | -38.36% | -8.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +81.69% | +24.71% |
| Average volume | 370.07K | 1.10M |
| Shares outstanding | 23.23M | 69.33M |
| Employees | 915 | 414 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RYTM has outperformed MDGL by 41.3 percentage points over the past year.
- Madrigal Pharmaceuticals is more profitable, keeping -30.1 cents of every revenue dollar as net income versus -103.6 cents for Rhythm Pharmaceuticals.
- Madrigal Pharmaceuticals grew revenue faster in its latest fiscal year (+432.05% vs +45.83%).
About Madrigal Pharmaceuticals
MDGL stock →Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees
About Rhythm Pharmaceuticals
RYTM stock →Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees
MDGL vs RYTM FAQ
Which is bigger, Madrigal Pharmaceuticals or Rhythm Pharmaceuticals?
Madrigal Pharmaceuticals (MDGL) is larger, with a market capitalization of $8.81B compared with $7.79B for Rhythm Pharmaceuticals (RYTM).
Which stock has performed better over the past year, MDGL or RYTM?
RYTM returned +10.44% over the past 12 months, compared with -30.82% for MDGL (price return, excluding dividends). Past performance does not predict future results.
Are Madrigal Pharmaceuticals and Rhythm Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.